PD-1 blockade has achieved the highest response rate in classical Hodgkin lymphoma and has also shown clinical activity in several types of B-cell non-Hodgkin lymphoma with variable PD-L1 expression, especially in CLL patients with Richter transformation [50, 51]. Here, PDCD1 is linked to Hodgkins lymphoma.